The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/IIa trial of the novel microtubule inhibitor BAL101553 in advanced solid tumors: Phase I completed.
L Rhoda Molife
Research Funding - Basilea
Georgios Imseeh
No relevant relationships to disclose
Marta Capelan
No relevant relationships to disclose
Fatima El-Khouly
No relevant relationships to disclose
Nicola Cresti
No relevant relationships to disclose
Alan David Smith
No relevant relationships to disclose
Dexter Averion
No relevant relationships to disclose
Noor Md. Haris
No relevant relationships to disclose
Sarah Jane Stimpson
No relevant relationships to disclose
Todd Gumbleton
No relevant relationships to disclose
Heidi A Lane
Employment or Leadership Position - Basilea
Stock Ownership - Basilea
Research Funding - Basilea
Felix Bachmann
Employment or Leadership Position - Basilea
Anne Schmitt-Hoffmann
Employment or Leadership Position - Basilea
Stock Ownership - Basilea
Alexandar Tzankov
No relevant relationships to disclose
Alison L. Hannah
Consultant or Advisory Role - Basilea
Stephanie Anderson
No relevant relationships to disclose
Ullrich Bette
Employment or Leadership Position - Basilea
Stock Ownership - Basilea
Alan Hilary Calvert
Consultant or Advisory Role - Basilea (U)
Other Remuneration - Basilea
Ruth Plummer
Research Funding - Basilea
Rebecca Sophie Kristeleit
Research Funding - Basilea